- AI-enabled antibody discovery engine for healthcare buyers
- Stays focused on real drug discovery buyer problems
- Scales to organization-wide healthcare rollouts
AbCellera
AI-enabled antibody discovery engine
SF7.7
SF Score editorial score across features, ease, and value, based on public reviews and product research. Learn more →
Accelerate molecule design cyclesPharma partners and antibody programs
Accelerate molecule design cyclesPharma partners and antibody programs
Best for
Pharma partners and antibody programs
Pricing
Custom
SoftFinders Score
7.7 / 10
Overview
What is AbCellera?
AbCellera is an antibody discovery company using AI and high-throughput data to find and develop antibody therapeutics with partners. The product is positioned around R&D acceleration and computational biology rather than guaranteed clinical outcomes, and engagement typically happens through pharma partnerships rather than self-serve subscription buying. Buyers should weigh data access requirements, expected timelines to validated leads, and the cost structure across collaborations before committing to a long discovery program today.
For pharma partners and antibody programs, AbCellera is worth a serious look thanks to AI-enabled antibody discovery engine. Just keep one limitation in view: engagement is partnership and pipeline-led. Pricing is sales-led and scoped per buyer rather than posted publicly. Verify EHR or workflow fit, scope, and support before committing.
KEY FEATURES
What you get out of the box
Molecule Design
Generates and ranks small molecule candidates
Protein Modeling
Predicts and designs protein structures
Knowledge Graph
Connects biological and chemical knowledge sources
Virtual Screening
Screens compound libraries against targets
Literature Intelligence
Mines biomedical literature for relevant evidence
Multi Omics
Integrates genomic and other omics data sources
USE CASES
Where teams put it to work
Accelerate molecule design cycles
Support protein engineering programs
Mine literature for research signals
Run virtual screens against targets
Collaborate with pharma partners
Bridge AI design and wet lab cycles
Editorial Take
What we like, and what to verify
- Engagement is partnership and pipeline-led
- Drug success still depends on downstream trials
- Pricing is sales-led and needs scoping upfront
Screenshots
A look inside
Alternatives
Tools to consider next
Iktos SF 7.4
Why consider it
Generative chemistry and synthesis planning AI
Cradle SF 7.5
Why consider it
AI protein design for wet labs
Chai Discovery SF 7.3
Why consider it
Molecular structure prediction for discovery research
NOETIK SF 7.1
Why consider it
Spatial biology models for cancer targets
Generate Biomedicines SF 7.7
Why consider it
Generative protein design across modalities
Causaly SF 7.6
Why consider it
Biomedical evidence and reasoning for R&D
FAQ